Table 3 Laboratory data and imaging findings of patients with COVID-19
|  | All patients (N = 91) | Local cases (n = 35) | Imported cases (n = 56) | P values |
|---|---|---|---|---|
Blood routine | ||||
 White cell count (× 109/L), Mean (SD) | 5.45 (2.42) | 5.57 (1.70) | 5.38 (2.79) | 0.502 |
   > 10.0 | 5 (5.5%) | 1 (2.9%) | 4 (7.1%) | 0.645 |
   < 4.0 | 21 (23.1%) | 5 (14.3%) | 16 (28.6%) | 0.116 |
 Lymphocytes (× 109/L), Mean (SD) | 1.26 (0.62) | 1.45 (0.59) | 1.14 (0.61) | 0.022 |
   < 1.1 | 39 (42.9%) | 8 (22.9%) | 31 (55.4%) | 0.002 |
 Platelets (×  109/L), Mean (SD) | 205.8 (69.9) | 239.7 (68.3) | 184.6 (62.6) | 0.001 |
   < 150 | 23 (25.3%) | 3 (8.3%) | 20 (35.7%) | 0.005 |
 Hemoglobin (g/L), Mean (SD) | 133.0 (18.1) | 131.7 (17.7) | 133.8 (18.5) | 0.412 |
Blood biochemistry | ||||
 Alanine aminotransferase (U/L, normal range 3–35), Median (IQR) | 21.3 (14.7–34.8) | 22.0 (15.0–31.0) | 20.7 (13.8–35.4) | 0.427 |
  Increased (n, %) | 20 (22.0%) | 6 (17.1%) | 14 (25.0%) | 0.379 |
 Aspartate aminotransferase (U/L, normal range 3–40), Median (IQR) | 22.0 (17.0–30.1) | 24.0 (20.0–32.0) | 20.0 (15.3–28.0) | 0.170 |
  Increased (n, %) | 12 (13.2%) | 4 (11.4%) | 8 (14.3%) | 0.761 |
 Total bilirubin (μmol/L, normal range 4.0–17.1), Median (IQR) | 9.0 (6.5–13.4) | 9.8 (5.9–13.9) | 8.4 (6.5–11.8) | 0.410 |
  Increased (n, %) | 13 (14.3%) | 3 (8.6%) | 10 (17.9%) | 0.218 |
 Albumin (g/L, normal range 35.0–55.0), Median (IQR) | 42.3 (36.2–47.1) | 46.7 (41.4–49.6) | 39.3 (34.7–44.4) | 0.001 |
  Decreased (n, %) | 18 (19.8%) | 4 (11.4%) | 14 (25.0%) | 0.114 |
 PT (sec), Median (IQR) | 11.3 (10.8–11.8) | 11.3 (10.3–12.4) | 11.4 (10.8–12.5) | 0.407 |
 Serum creatinine (μmol/L), Median (IQR) | 65.8 (48.0–76.9) | 68.0 (50.9–77.0) | 59.0 (47.0–76.8) | 0.835 |
 Creatine kinase (U/L), Median (IQR) | 63.0 (46.0–93.6) | 70.0 (46.0–127.0) | 62.0 (45.0–84.0) | 0.013 |
 C-reaction protein (mg/L), Median (IQR) | 12.3 (2.2–45.1) | 5.3 (1.2–30.5) | 17.0 (3.0–51.3) | 0.022 |
 Procalcitonin (ng/mL), Median (IQR) | 0.04 (0.02–0.06) | 0.04 (0.02–0.09) | 0.03 (0.01–0.06) | 0.778 |
Chest CT finding | ||||
 Unilateral pneumonia | 16 (17.6%) | 8 (22.9%) | 8 (14.3%) | 0.296 |
 Bilateral pneumonia | 75 (82.4%) | 27 (77.1%) | 48 (85.7%) | 0.296 |
 Lung periphery | 79 (86.8%) | 29 (82.9%) | 50 (89.3%) | 0.526 |
 Ground-glass opacity | 80 (87.9%) | 30 (85.7%) | 50 (89.3%) | 0.743 |
 Multiple Infiltration | 76 (83.5%) | 26 (74.3%) | 50 (89.3%) | 0.061 |
 Bilateral lung periphery ground-glass opacity | 70 (76.9%) | 25 (71.4%) | 45 (80.4%) | 0.325 |
 Nodule | 11 (12.1%) | 2 (5.7%) | 9 (16.1%) | 0.193 |
 Lung consolidation | 8 (8.8%) | 3 (8.6%) | 5 (8.9%) | 1.000 |
 Pleural effusion | 2 (2.2%) | 0 (0.0%) | 2 (3.6%) | 0.521 |